Lei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lei Zhang has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Ao Gong
Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong 250012, PR China; Second Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250012, PR China
6 shared publicationsXiaojie Ma
College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China
6 shared publications- Changjun Chen
Department of Orthopaedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, People’s Republic of China
5 shared publications Yu Fu
Department of Orthopedic Surgery, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, China
5 shared publicationsLin-Song Teng
Second Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan, 250001, China
4 shared publicationsCaiwei Wang
Key Laboratory of Infection Immunity and Disease Intervention of Shandong Province, and Key Laboratory for Experimental Teratology of the Chinese Ministry of Education, School of Basic Medical Science, Cheeloo College of Medicine, Shandong University, Jinan, China
3 shared publications
Latest Publications
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- 11 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (875)
Dual inhibition of TNF-α and IL-1β signaling through BIG2 ameliorates osteoarthritis in mouse and primate models
Osteoarthritis (OA), a leading cause of disability, is characterized by chronic low-grade inflammation and metabolic dysregulation in chondrocytes. TNF-α and IL-1β are key inflammatory drivers in OA pathogenesis, but clinical trials targeting them individually have been unsuccessful, highlighting the potential need for dual-targeting strategies. By screening a US Food and Drug Administration–approved drug library, we identified dabigatran, a thrombin inhibitor, as a potent dual suppressor of TNF-α and IL-1β signaling that restored chondrocyte metabolism. In preclinical OA models, including both mice and cynomolgus macaques, dabigatran attenuated cartilage degeneration, alleviated pain, and improved joint function. To elucidate the molecular mechanisms, we performed biochemical copurification coupled with mass spectrometry, identifying brefeldin A–inhibited guanine nucleotide–exchange protein 2 (BIG2) as a previously unknown dabigatran-binding target. Mechanistically, dabigatran binds to BIG2, promoting BIG2-dependent TNFR1 release to dampen TNF-α signaling while enhancing BIG2-mediated IL-1R1 degradation through the autophagy-lysosome pathway to limit IL-1β effects. These findings establish BIG2-mediated receptor trafficking and membrane dynamics as a regulatory node that concurrently inhibits TNF-α and IL-1β signaling, suggesting this pathway as a potential therapeutic strategy for OA.
- Open Access
- 9 November 2026
- Published by Wiley in Advanced Science
Microenvironment‐Responsive Biomimetic Hydrogels Delivering Cistanche Deserticola‐Derived Nanovesicles for Intervertebral Disc Degeneration
Intervertebral disc degeneration (IVDD) is driven by persistent oxidative stress and tissue acidosis, accelerating nucleus pulposus cell (NPC) senescence and extracellular matrix (ECM) degradation. While plant‐derived nanovesicles (PDNVs) hold therapeutic promise, rapid clearance and mechanical leakage constrain their translation. Here, natural nanovesicles from Cistanche deserticola (CDNVs) were incorporated into an injectable, microenvironment‐responsive hydrogel (HAPOCS@CDNVs) for localized, sustained delivery. Dynamic Schiff base and phenylboronate ester crosslinks provide biomechanical buffering, scavenge reactive oxygen species (ROS), and trigger on‐demand CDNV release under acidic and oxidative conditions. Mechanistically, CDNVs alleviate oxidative stress, support mitochondrial function, and inhibit NF‐κB activation, thereby suppressing the senescence‐associated secretory phenotype (SASP) and preserving ECM homeostasis. In a rat IVDD model, a single intradiscal injection of HAPOCS@CDNVs sustained disc height, preserved tissue hydration, and retarded degeneration over 8 weeks. This platform provides a promising, minimally invasive strategy for disc repair.
- 9 November 2026
- Published by Wiley in Advanced Science
Open AccessMicroenvironment‐Responsive Biomimetic Hydrogels Delivering Cistanche Deserticola‐Derived Nanovesicles for Intervertebral Disc Degeneration
Intervertebral disc degeneration (IVDD) is driven by persistent oxidative stress and tissue acidosis, accelerating nucleus pulposus cell (NPC) senescence and extracellular matrix (ECM) degradation. While plant‐derived nanovesicles (PDNVs) hold therapeutic promise, rapid clearance and mechanical leakage constrain their translation. Here, natural nanovesicles from Cistanche deserticola (CDNVs) were incorporated into an injectable, microenvironment‐responsive hydrogel (HAPOCS@CDNVs) for localized, sustained delivery. Dynamic Schiff base and phenylboronate ester crosslinks provide biomechanical buffering, scavenge reactive oxygen species (ROS), and trigger on‐demand CDNV release under acidic and oxidative conditions. Mechanistically, CDNVs alleviate oxidative stress, support mitochondrial function, and inhibit NF‐κB activation, thereby suppressing the senescence‐associated secretory phenotype (SASP) and preserving ECM homeostasis. In a rat IVDD model, a single intradiscal injection of HAPOCS@CDNVs sustained disc height, preserved tissue hydration, and retarded degeneration over 8 weeks. This platform provides a promising, minimally invasive strategy for disc repair.
- 6 March 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 249, 14-26
Repurposing the hERG activator NS-1643 as a ferroptosis-targeting therapeutic against doxorubicin cardiotoxicity
- 6 March 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 249, 14-26
Repurposing the hERG activator NS-1643 as a ferroptosis-targeting therapeutic against doxorubicin cardiotoxicity
- Open Access
- 17 February 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (3) , 891-915
Histone demethylase KDM4B epigenetically controls NLRP3 expression to enhance inflammatory responses
NLRP3 inflammasome, the archetypical molecular driver of inflammation, plays crucial roles in host defense and maintaining cellular homeostasis. Demethylation of histone 3 lysine 9 trimethylation (H3K9me3, the repressive mark for euchromatic genes) is essential for activating gene transcription. However, whether H3K9 demethylation is required for the induction of proinflammatory cytokines remains largely unknown. Here, we show that histone demethylase lysine-specific demethylase 4B (KDM4B) mediates H3K9me3 demethylation at the Nlrp3 promoter to induce NLRP3 expression, thereby selectively enhancing NLRP3 inflammasome activation without affecting NF-κB activation. Concordantly, both Kdm4b deficiency and the selective KDM4 inhibitor ML324 inhibit NLRP3 inflammasome activation and ameliorate NLRP3-dependent inflammatory diseases in vivo. Furthermore, high glucose level upregulates KDM4B, promoting NLRP3 inflammasome activation and IL-1β secretion, thus aggravating aberrant inflammation during viral infections. Our findings reveal the role of H3K9me3 demethylation in initiating inflammation, identify KDM4B as an epigenetic accelerator of NLRP3, and propose that modulating H3K9me3 could represent a targeted anti-inflammatory strategy.
- 17 February 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (3) , 891-915
Open AccessHistone demethylase KDM4B epigenetically controls NLRP3 expression to enhance inflammatory responses
NLRP3 inflammasome, the archetypical molecular driver of inflammation, plays crucial roles in host defense and maintaining cellular homeostasis. Demethylation of histone 3 lysine 9 trimethylation (H3K9me3, the repressive mark for euchromatic genes) is essential for activating gene transcription. However, whether H3K9 demethylation is required for the induction of proinflammatory cytokines remains largely unknown. Here, we show that histone demethylase lysine-specific demethylase 4B (KDM4B) mediates H3K9me3 demethylation at the Nlrp3 promoter to induce NLRP3 expression, thereby selectively enhancing NLRP3 inflammasome activation without affecting NF-κB activation. Concordantly, both Kdm4b deficiency and the selective KDM4 inhibitor ML324 inhibit NLRP3 inflammasome activation and ameliorate NLRP3-dependent inflammatory diseases in vivo. Furthermore, high glucose level upregulates KDM4B, promoting NLRP3 inflammasome activation and IL-1β secretion, thus aggravating aberrant inflammation during viral infections. Our findings reveal the role of H3K9me3 demethylation in initiating inflammation, identify KDM4B as an epigenetic accelerator of NLRP3, and propose that modulating H3K9me3 could represent a targeted anti-inflammatory strategy.
- Open Access
- 18 November 2025
- Published by Wiley in Orthopaedic Surgery
- Vol. 17 (12) , 3456-3467
Selenium Attenuates Dexamethasone‐Induced Osteoblast Dysfunction and Prevents Femoral Head Osteonecrosis via PI3K / AKT / GSK3β Pathway Activation
Objective: Glucocorticoid‐induced osteonecrosis of the femoral head (GC‐ONFH) represents a devastating complication of steroid therapy, primarily driven by osteoblast apoptosis and impaired osteogenesis. Although selenium (Se) is renowned for its potent bone‐protective properties, its therapeutic potential, and specific mechanisms in GC‐ONFH remain largely unexplored and thus require further investigation. Methods: To assess the therapeutic effectiveness of oral selenium supplementation in GC‐ONFH, a rat model of GC‐ONFH was utilized. The rats were randomly allocated into three groups ( n = 6 per group): (1) Control group, (2) Methylprednisolone sodium succinate (MPS) group, and (3) Se group. The intervention was carried out for 4 weeks. In vitro experiments utilized primary rat osteoblasts and MC3T3‐E1 cells to elucidate the mechanisms through which selenium mitigates dexamethasone (DEX)‐induced alterations in cell proliferation, apoptosis, and osteogenic differentiation. The assessments were conducted using micro‐CT and histomorphometry, CCK‐8 assays and flow cytometry, as well as RT–qPCR, Western blotting, and immunofluorescence. Results: Selenium supplementation effectively prevented trabecular collapse and significantly reduced the number of empty lacunae in rats with GC‐ONFH. Specifically, an optimal dose of 10 μmol Se successfully reversed the damage induced by DEX, including the restoration of cell proliferation, suppression of apoptosis, and rescue of osteogenic activity. Mechanistically, Se counteracts the DEX‐induced suppression of phosphorylated phosphatidylinositol 3‐kinase (p‐PI3K), phosphorylated protein kinase B (p‐AKT), and phosphorylated glycogen synthase kinase 3β (GSK3β) (p‐GSK3β), thereby activating the PI3K/AKT/GSK3β signaling pathway, which promotes cell proliferation, inhibits apoptosis, and enhances osteogenesis in osteoblasts. Conclusion: Selenium can activate the PI3K/AKT/GSK3β pathway, reverse DEX‐induced hypoproliferation and apoptosis, restore osteogenic capacity, prevent trabecular collapse, and attenuate GC‐ONFH in rat models. Our findings demonstrate that selenium supplementation can be regarded as a clinically applicable strategy for impeding the progression of GC‐ONFH in at‐risk patients.
- 18 November 2025
- Published by Wiley in Orthopaedic Surgery
- Vol. 17 (12) , 3456-3467
Open AccessSelenium Attenuates Dexamethasone‐Induced Osteoblast Dysfunction and Prevents Femoral Head Osteonecrosis via PI3K / AKT / GSK3β Pathway Activation
Objective: Glucocorticoid‐induced osteonecrosis of the femoral head (GC‐ONFH) represents a devastating complication of steroid therapy, primarily driven by osteoblast apoptosis and impaired osteogenesis. Although selenium (Se) is renowned for its potent bone‐protective properties, its therapeutic potential, and specific mechanisms in GC‐ONFH remain largely unexplored and thus require further investigation. Methods: To assess the therapeutic effectiveness of oral selenium supplementation in GC‐ONFH, a rat model of GC‐ONFH was utilized. The rats were randomly allocated into three groups ( n = 6 per group): (1) Control group, (2) Methylprednisolone sodium succinate (MPS) group, and (3) Se group. The intervention was carried out for 4 weeks. In vitro experiments utilized primary rat osteoblasts and MC3T3‐E1 cells to elucidate the mechanisms through which selenium mitigates dexamethasone (DEX)‐induced alterations in cell proliferation, apoptosis, and osteogenic differentiation. The assessments were conducted using micro‐CT and histomorphometry, CCK‐8 assays and flow cytometry, as well as RT–qPCR, Western blotting, and immunofluorescence. Results: Selenium supplementation effectively prevented trabecular collapse and significantly reduced the number of empty lacunae in rats with GC‐ONFH. Specifically, an optimal dose of 10 μmol Se successfully reversed the damage induced by DEX, including the restoration of cell proliferation, suppression of apoptosis, and rescue of osteogenic activity. Mechanistically, Se counteracts the DEX‐induced suppression of phosphorylated phosphatidylinositol 3‐kinase (p‐PI3K), phosphorylated protein kinase B (p‐AKT), and phosphorylated glycogen synthase kinase 3β (GSK3β) (p‐GSK3β), thereby activating the PI3K/AKT/GSK3β signaling pathway, which promotes cell proliferation, inhibits apoptosis, and enhances osteogenesis in osteoblasts. Conclusion: Selenium can activate the PI3K/AKT/GSK3β pathway, reverse DEX‐induced hypoproliferation and apoptosis, restore osteogenic capacity, prevent trabecular collapse, and attenuate GC‐ONFH in rat models. Our findings demonstrate that selenium supplementation can be regarded as a clinically applicable strategy for impeding the progression of GC‐ONFH in at‐risk patients.
- 5 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111724
Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury
- 5 September 2025
- Published by Elsevier in Chemico-Biological Interactions
- Vol. 421, 111724
Formoterol, a clinically approved drug, inhibits ferroptosis by suppressing lipid peroxidation and attenuates APAP-induced acute liver injury
- 12 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108874
Discovery of 8-hydroxy-tetrahydroquinoline ferroptosis inhibitors for the treatment of acute kidney injury
- 12 August 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 164, 108874
Discovery of 8-hydroxy-tetrahydroquinoline ferroptosis inhibitors for the treatment of acute kidney injury
- Open Access
- 10 March 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-12
Ghrelin increases cis-platinum resistance and promotes aggressiveness of osteosarcoma by activating AKT and Wnt/β-catenin pathways
Osteosarcoma (OS) is the most common primary bone malignancy because of its extra high tendency of metastasis. In-depth research is needed to uncover the pathogenesis of patients with OS cells. We collected 74 tissue samples from patients with OS cells and measured the expression levels of ghrelin by immunohistochemistry. Ghrelin was added into OS cell lines in CCK8 assays, JC-1 staining and Western blot analysis were performed to explore its effect on the aggressiveness of OS cells and drug resistance. To determine its function, ghrelin was overexpressed or knocked down in OS cells and then detect cell proliferation in the xenograft mouse model and orthotopic model. Western blot analysis was performed to explore ghrelin-regulated signal pathways. In this work, we identified the relation between the level of ghrelin expression and poor prognosis of OS patients. As well as promoting proliferation, migration, and invation, ghrelin promotes the survival of OS in vitro as well as in vivo, and reduces the apoptosis of OS cells. What’s more, ghrelin increases the resistance of cis-platinum by changing mitochondrial function and decreases the expression of MDR-1. Above all, these results demonstrated ghrelin exerts tumorigenic and metastatic effects and may be a potential therapeutic target.
- 10 March 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-12
Open AccessGhrelin increases cis-platinum resistance and promotes aggressiveness of osteosarcoma by activating AKT and Wnt/β-catenin pathways
Osteosarcoma (OS) is the most common primary bone malignancy because of its extra high tendency of metastasis. In-depth research is needed to uncover the pathogenesis of patients with OS cells. We collected 74 tissue samples from patients with OS cells and measured the expression levels of ghrelin by immunohistochemistry. Ghrelin was added into OS cell lines in CCK8 assays, JC-1 staining and Western blot analysis were performed to explore its effect on the aggressiveness of OS cells and drug resistance. To determine its function, ghrelin was overexpressed or knocked down in OS cells and then detect cell proliferation in the xenograft mouse model and orthotopic model. Western blot analysis was performed to explore ghrelin-regulated signal pathways. In this work, we identified the relation between the level of ghrelin expression and poor prognosis of OS patients. As well as promoting proliferation, migration, and invation, ghrelin promotes the survival of OS in vitro as well as in vivo, and reduces the apoptosis of OS cells. What’s more, ghrelin increases the resistance of cis-platinum by changing mitochondrial function and decreases the expression of MDR-1. Above all, these results demonstrated ghrelin exerts tumorigenic and metastatic effects and may be a potential therapeutic target.
- 21 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113855
Regulation of macrophage polarization and pyroptosis by 4-methylcatechol alleviates collagen-induced arthritis via Nrf2/HO-1 and NF-κB/NLRP3 signaling pathways
- 21 December 2024
- Published by Elsevier in International Immunopharmacology
- Vol. 146, 113855
Regulation of macrophage polarization and pyroptosis by 4-methylcatechol alleviates collagen-induced arthritis via Nrf2/HO-1 and NF-κB/NLRP3 signaling pathways
- Open Access
- 30 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
ZC3HAV1 facilitates STING activation and enhances inflammation
Stimulator of interferon genes (STING) is vital in the cytosolic DNA-sensing process and critical for initiating the innate immune response, which has important functions in host defense and contributes to the pathogenesis of inflammatory diseases. Zinc finger CCCH-type antiviral protein 1 (ZC3HAV1) specifically binds the CpG dinucleotides in the viral RNAs of multiple viruses and promotes their degradation. ZAPS (ZC3HAV1 short isoform) is a potent stimulator of retinoid acid-inducible gene I (RIG-I) signaling during the antiviral response. However, how ZC3HAV1 controls STING signaling is unclear. Here, we show that ZC3HAV1 specifically potentiates STING activation by associating with STING to promote its oligomerization and translocation from the endoplasmic reticulum (ER) to the Golgi, which facilitates activation of IRF3 and NF-κB pathway. Accordingly, Zc3hav1 deficiency protects mice against herpes simplex virus-1 (HSV-1) infection- or 5,6-dimethylxanthenone-4-acetic acid (DMXAA)-induced inflammation in a STING-dependent manner. These results indicate that ZC3HAV1 is a key regulator of STING signaling, which suggests its possible use as a therapeutic target for STING-dependent inflammation.
- 30 October 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-11
Open AccessZC3HAV1 facilitates STING activation and enhances inflammation
Stimulator of interferon genes (STING) is vital in the cytosolic DNA-sensing process and critical for initiating the innate immune response, which has important functions in host defense and contributes to the pathogenesis of inflammatory diseases. Zinc finger CCCH-type antiviral protein 1 (ZC3HAV1) specifically binds the CpG dinucleotides in the viral RNAs of multiple viruses and promotes their degradation. ZAPS (ZC3HAV1 short isoform) is a potent stimulator of retinoid acid-inducible gene I (RIG-I) signaling during the antiviral response. However, how ZC3HAV1 controls STING signaling is unclear. Here, we show that ZC3HAV1 specifically potentiates STING activation by associating with STING to promote its oligomerization and translocation from the endoplasmic reticulum (ER) to the Golgi, which facilitates activation of IRF3 and NF-κB pathway. Accordingly, Zc3hav1 deficiency protects mice against herpes simplex virus-1 (HSV-1) infection- or 5,6-dimethylxanthenone-4-acetic acid (DMXAA)-induced inflammation in a STING-dependent manner. These results indicate that ZC3HAV1 is a key regulator of STING signaling, which suggests its possible use as a therapeutic target for STING-dependent inflammation.